Last reviewed 2026-04-22 · How we verify

CM326

CM326 is a monoclonal antibody that targets and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.

CM326 is a monoclonal antibody that targets and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).

At a glance

Mechanism of action

CM326 binds to OX40 (CD134) on activated T cells, providing co-stimulatory signals that enhance T-cell proliferation, survival, and effector function. By agonizing OX40, the drug promotes anti-tumor immune responses and can be used as a monotherapy or in combination with other immunotherapies to overcome immune suppression in the tumor microenvironment.

Approved indications

• Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)

Common side effects

• Immune-related adverse events (irAEs)
• Fatigue
• Rash
• Diarrhea

Key clinical trials

• A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis (PHASE3)
• A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2)
• A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma (PHASE3)
• Study of CM326 Injection in Healthy Subjects (PHASE1)
• A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps (PHASE1, PHASE2)
• Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis (PHASE2)
• A Study of CM326 in Subjects With Moderate to Severe Asthma (PHASE2)
• The Study of CM326 in Adult Subjects With Atopic Dermatitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.